PEB CEO, David Darling, Announces Intention to Retire

Company Announcement
12 April 2021



PACIFIC EDGE CEO, DAVID DARLING, ANNOUNCES INTENTION TO RETIRE

Pacific Edge Limited (NZX: PEB) announces that CEO, David Darling, has advised the company’s Board that he
intends to retire from his role on 6 April 2022. Following this, David will continue to support the company in a
consulting role.

The Board wishes to acknowledge the outstanding contribution David has made to Pacific Edge over the last 18
years and the passion and sustained energy he has brought to the role over that very long period of time. Chairman
Chris Gallaher, said that Dave’s expertise, persistence, and perseverance in the face of challenges over a long period
of time have marked him as an outstanding CEO.

“During his tenure, Pacific Edge has grown from a research concept to a fully-fledged commercial entity well
positioned to deliver the global growth potential of its technology. Dave has been the driving contributor to the
development and execution of Pacific Edge’s global strategy and lead the achievement of major commercial
milestones in a highly competitive global market. He leaves the company in a strong position as we take the next
steps in our commercial journey.”

David Darling commented: “It has been a great privilege to have worked with such an outstanding team over the
past 18 years, all of whom share the same passion for delivering better ways to diagnose and monitor cancer. Pacific
Edge has a fantastic team, with proven performance and is well positioned to deliver the significant growth
opportunities ahead of it. With the achievement of several major commercial milestones, the company is now in a
new stage in its evolution. I believe that it is the right time for me to begin the process of succession to ensure a
seamless transition over the next 12 months. I look forward to seeing the company’s continued growth and
development in the ensuring years.”

The Board will commence a formal process to appoint the best and most capable person to fill this role and will
update the market in due course.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

Company Announcement
12 April 2021




ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.